Prof Greg Hannon elected Fellow of the AACR Academy Class of 2020

Institute Director Prof Greg Hannon has joined 19 leading cancer researchers to be elected Fellows of the American Association for Cancer Research (AACR) Academy.
The mission of the AACR Academy is to recognise and honour distinguished scientists whose scientific contributions have propelled significant innovation and progress against cancer. Fellows of the AACR Academy serve as a global brain trust in the cancer field, helping to advance the mission of the AACR to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.
Professor Greg Hannon has been recognised for fundamental contributions to characterizing the role of cyclin-dependent kinases and small RNAs including microRNAs, piwi-interacting, and short-hairpin RNAs in cell cycle regulation, carcinogenesis, and drug development.
All Fellows are nominated and elected through an annual peer review process conducted by existing Fellows of the AACR Academy and ratified by the AACR Academy Steering Committee and AACR Executive Committee. This process involves a rigorous assessment of each candidate’s scientific accomplishments in cancer research and cancer-related sciences. Only individuals whose work has had a significant and enduring impact on cancer research are considered for election and induction into the AACR Academy.
“This year’s collection of elected Fellows of the AACR Academy continues the AACR’s rich tradition of recognizing the most significant contributors to cancer research,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “The 2020 class consists of 19 trailblazing pioneers in various scientific areas who have accelerated the pace of progress against cancer. We are honored to have them join our 212 existing Fellows and look forward to celebrating their scientific accomplishments.”
Related News
See all news-
Sir Shankar Balasubramanian elected Fellow of the AACR Academy
10th March 2025
Sir Shankar has been recognised for his pioneering research in nucleic acid chemistry and his key role in the development of next-generation sequencing technology.
Find out more -
Richard Mair joins Institute as an Independent Clinical Fellow
10th February 2025
Richard will build a research group at the Institute to focus on IDH mutant astrocytoma, , a common type of brain tumour that accounts for 9% of brain tumour diagnoses.
Find out more -
Imaging technique allows rapid assessment of ovarian cancer subtypes and their response to treatment
6th December 2024
An MRI-based imaging technique developed at the Institute predicts the response of ovarian cancer tumours to treatment, and rapidly reveals how well treatment is working, in patient-derived cell models.
Find out more